Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free TCRT Stock Alerts

Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$2.85 -0.21 (-6.86%)
Closing price 03:56 PM Eastern
Extended Trading
$2.90 +0.05 (+1.79%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TCRT vs. VYNE, KZIA, HOWL, AEON, and ANEB

Should you buy Alaunos Therapeutics stock or one of its competitors? MarketBeat compares Alaunos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alaunos Therapeutics include VYNE Therapeutics (VYNE), Novogen (KZIA), Werewolf Therapeutics (HOWL), AEON Biopharma (AEON), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry.

How does Alaunos Therapeutics compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alaunos Therapeutics has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$570K39.90-$26.48M-$0.38N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

Alaunos Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-4,726.21% -70.42% -63.46%
Alaunos Therapeutics N/A -165.94%-123.50%

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the broader market.

In the previous week, Alaunos Therapeutics had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 5 mentions for Alaunos Therapeutics and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.87 beat Alaunos Therapeutics' score of 0.73 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
VYNE Therapeutics Very Positive
Alaunos Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

VYNE Therapeutics beats Alaunos Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Novogen's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Alaunos Therapeutics N/A -165.94%-123.50%

Novogen presently has a consensus price target of $21.00, indicating a potential upside of 64.32%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics has lower revenue, but higher earnings than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$30K702.90-$13.41MN/AN/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

In the previous week, Alaunos Therapeutics had 3 more articles in the media than Novogen. MarketBeat recorded 5 mentions for Alaunos Therapeutics and 2 mentions for Novogen. Novogen's average media sentiment score of 0.94 beat Alaunos Therapeutics' score of 0.73 indicating that Novogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alaunos Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

30.9% of Novogen shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novogen has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the broader market.

Summary

Novogen beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Werewolf Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Alaunos Therapeutics has higher earnings, but lower revenue than Werewolf Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A
Werewolf Therapeutics$1.88M11.63-$60.82M-$1.24N/A

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 5 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.73 beat Werewolf Therapeutics' score of 0.14 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alaunos Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Werewolf Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 733.33%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -165.94% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -165.94% -123.50%
Werewolf Therapeutics N/A -208.23%-75.12%

Summary

Werewolf Therapeutics beats Alaunos Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to AEON Biopharma?

Alaunos Therapeutics (NASDAQ:TCRT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

In the previous week, Alaunos Therapeutics had 3 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for Alaunos Therapeutics and 2 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.00 beat Alaunos Therapeutics' score of 0.73 indicating that AEON Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alaunos Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AEON Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AEON Biopharma's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -165.94% -123.50%
AEON Biopharma N/A N/A -994.63%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

AEON Biopharma beats Alaunos Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.13, suggesting that its share price is 213% less volatile than the broader market.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anebulo PharmaceuticalsN/A -74.57% -68.96%
Alaunos Therapeutics N/A -165.94%-123.50%

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

In the previous week, Alaunos Therapeutics had 5 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Alaunos Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Alaunos Therapeutics' average media sentiment score of 0.73 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Anebulo Pharmaceuticals Neutral
Alaunos Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anebulo Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Anebulo Pharmaceuticals beats Alaunos Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

Export
MetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$69.60M$3.02B$6.41B$12.58B
Dividend YieldN/A1.97%2.75%5.26%
P/E Ratio-1.3417.5421.2526.28
Price / SalesN/A342.17561.59114.77
Price / CashN/A56.3143.4956.90
Price / Book57.006.3110.607.33
Net Income-$4.18M$75.84M$3.56B$337.06M
7 Day Performance17.77%3.33%2.84%3.43%
1 Month Performance13.10%2.07%6.16%7.24%
1 Year Performance10.47%32.78%36.73%37.98%

Alaunos Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
1.0782 of 5 stars		$2.85
-6.9%		N/A+23.4%$69.60MN/AN/A40
VYNE
VYNE Therapeutics
1.1577 of 5 stars		$0.68
+0.2%		N/A-29.5%$22.57M$570KN/A30
KZIA
Novogen
2.7433 of 5 stars		$13.17
+1.5%		$21.00
+59.5%		+255.9%$21.44M$30KN/A12
HOWL
Werewolf Therapeutics
3.0778 of 5 stars		$0.42
-3.6%		$3.75
+787.8%		-62.6%$21.28M$1.88MN/A40
AEON
AEON Biopharma
1.7628 of 5 stars		$0.82
-4.8%		N/A+15.7%$20.78MN/A4.565

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel